share_log

Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $220 Price Target

Benzinga ·  Oct 12 01:12  · Ratings

Cantor Fitzgerald analyst Olivia Brayer reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and maintains $220 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment